

DRUG DISCOVERY ET ONCOLOGIE

UN FOCUS SUR LES PARTENARIATS PUBLICS-PRIVÉS



Introduction table-ronde / Stéphane Huet

5 Avril 2019, Lyon

Sous l'égide de la

**FONDATION
BULLUKIAN**


DE L'IDENTIFICATION DE LA CIBLE JUSQU'AU CANDIDAT MÉDICAMENT



**Candidat
Médicament**

LA MAJORITÉ DES CANDIDATS MEDICAMENTS ÉVALUÉS EN PHASE II ECHOUE SUR L'OBJECTIF "EFFICACITÉ"

Phase II Failures in 2008-2011



Nature Reviews | Drug Discovery

Nature Reviews Drug Discovery 10, 328-329, 2011

- Les modèles utilisés pour sélectionner la cible étaient-ils pertinents - notamment de la pathologie?
- Le niveau de validation de la cible était-il suffisant?
- Un problème d'innovation?

UNE OUVERTURE DE L'INDUSTRIE VERS LE MONDE ACADEMIQUE AUTOUR DE 2010

- Amgen, Academic Collaborations <http://www.amgen.com/partnerships/academic-collaborations/>
- AstraZeneca
 - Target Innovation <https://openinnovation.astrazeneca.com/openinnovation.html>
 - Clinical Compound Bank <https://openinnovation.astrazeneca.com/openinnovation/clinical-compound-bank.html>
 - Preclinical Toolbox <https://openinnovation.astrazeneca.com/openinnovation/preclinical-toolbox.html>
 - New Molecular Profiling <https://openinnovation.astrazeneca.com/new-molecular-profiling.html>
- AstraZeneca - Francis Crick Institute, Open science partnership
 - <https://www.crick.ac.uk/news/cricknews/issuing-translating-translation/>
- AstraZeneca - Academic Drug Discovery Consortium (ADD) <http://addconsortium.org/interior-partnerships-az.php>
- Bayer
 - Grants4Targets Pharmaceuticals <https://innovate.bayer.com/what-we-offer/grants4targets-pharmaceuticals/cals/>
 - Bayer, West Coast Innovation Center U.S. <https://innovate.bayer.com/what-we-offer/west-coast-innovation-center-united-states/>
- Boehringer Ingelheim <https://www.boehringer-ingelheim.com/partnering/partnering-interests>
- Eisai, Investigator Initiated Studies <http://www.eisaigrants.com/>
- Eli Lilly, Open Innovation Drug Discovery
- GSK, DPAC <http://www.dpac.gsk.com/>

Your idea
Our resources

Target Innovation
Do you have an innovative drug discovery idea?

Submit your opportunities
Our collaboration process

UNE OUVERTURE DE L'INDUSTRIE VERS LE MONDE ACADEMIQUE AUTOUR DE 2010

- Novartis
 - **Novartis Pharmaceuticals** <https://external-novartis.idea-point.com/Pharma->
- Novo Nordisk, Innovation Partnering
 - <http://www.novonordisk.com/rnd/R-D-Partnerships/>
- Innovative Medicines Initiative (IMI), European I
 - <https://www.imi.europa.eu/commission-head-factory>
- Johnson + Johnson, JLABS, JLINKS, Johnson Centers, J
 - <https://www.jnjinnovation.com/partnering/pha>
- Merck, Investigator Studies Program <http://engagezo>
- MRC, MRC-Industry Asset Sharing Initiative <https://initiative/mrc-industry-asset-sharing-initiative/>
- Pfizer
 - **Competitive Grants** <http://www.pfizer.co>
 - **Investigator-Initiated Research** <http://www.pfizer.co> initiated-research
- Sanofi , Open Partnering <http://en.sanofi.com/r>
- Takeda, Investigator Initiated Studies <https://www.tan-development/investigator-initiated-sponsored-research/>

SUBMIT YOUR IDEAS
 Got an idea for an IMI project? Submit your proposal by filling in a simple form.

Oncology
 Cancer remains a leading cause of death worldwide.
 We are building on our strong heritage in oncology research to pursue curative approaches.
 We seek collaborations focusing on our key strategy of novel therapeutic approaches.

Investigator Initiated Sponsored Research

Our collaboration process

Submit your opportunities

INVESTIGATOR SPONSORED RESEARCH

Areas of Interest

Oncology Areas of Interest

Rare Disease Areas of Interest

Targeted therapy resistance (induced or intrinsic)

Novel lineage targets and drugs targeting them



Active Immunization and Antibody Directed Tumor Targeting

- Stimulation of functional activity of antigen presenting cells
- Redirection of immunity against tumors using cell engagers & immuno-conjugates
- Innovative pattern recognition receptors (PRRs) and agonists and adjuvants

DES LABOS PHARMACEUTIQUES QUI PROPOSENT DES “CHALLENGES” COMPETITIFS

- AstraZeneca, InnoCentive
<https://openinnovation.astrazeneca.com/challenges.html>
- Daiichi-Sankyo, TaNeDS Europe <http://www.daiichisankyo.com/rd/taneds/>
- Eli Lilly
 - Lilly Research Award Program <https://www.lilly.com/lilly-research-award-program>
- GSK, Discovery Fast Track Challenge <http://openinnovation.gsk.com/>
- Innovative Medicines Initiative (IMI)/ EU, Calls for Proposals
 - <https://www.imi.europa.eu/content/overview-imis-calls-how-participate>
- Merck, Innovation Network <http://engagezone.msd.com/mint.php>
- Sanofi (US), Sanofi Innovation Awards (iAwards)
 - <http://innovation.partners.org/about/special-programs/sanofi-iawards-call-for-proposals>
- Takeda, Innovators in Science Award
<http://www.nyas.org/awards/takedainnovators.aspx>

UNE CROISSANCE EXPONENTIELLE DES CENTRES ACADÉMIQUES DE DRUG DISCOVERY



<http://addconsortium.org/>

Source: ChemBioFrance

DES PLATEFORMES DRUG DISCOVERY AU SERVICE DES CHERCHEURS ACADEMIQUES

CD3 (KU LEUVEN)

- Partnerships with academia, spin-off companies and Pharma
- Start Point:
 - Early research
- Offering:
 - Assay development
 - Compound screening
- End Point:
 - Licensing to a Pharma

CD3 closes 60 million euro fund to turn academic research into new medicines.

LEAD DISCOVERY CENTER (DORTMUND)

- Partnerships with academia
- Start Point:
 - Early research
- Offering:
 - Assay development
 - Compound screening
 - Pharmacology
- End Point:
 - Licensing to a Biotech / Pharma

DUNDEE UNIVERSITY

Innovative Targets Portfolio



Plateformes DD France

- Souvent locales à l'initiative d'Instituts : Imagine, Vision, iSTEM, Curie, CEA, C3D.....



THÈMES DE DISCUSSION TABLE RONDE

- Partage d'expérience de partenariat
- Risques / Bénéfices pour les partenaires (académique, cellule de valorisation, industriel)
- Comment mettre en place une politique partenariale
- Les plateformes Drug Discovery académiques: valeur ajoutée / limites
- Combien cela coûte ? Quelles sont les chances de succès?
- Que faudrait-il changer dans les PPP?

BRONZE

Cluster
Management
Excellence

STRIVING FOR CLUSTER EXCELLENCE



Bâtiment Domilyon – 5ème étage
321 avenue Jean Jaurès F69007 LYON

www.canceropole-clara.com
04 37 90 17 10 - [infos@canceropole-](mailto:infos@canceropole-clara.com)



L'INNOVATION AU SERVICE DE LA LUTTE CONTRE LE CANCER



Sous l'égide de la

FONDATION
BULLUKIAN

